Prostate Health Index (phi)
Serum p2PSA, total PSA and free PSA index used as an aid in distinguishing prostate cancer from benign prostatic conditions in the FDA-approved population.
- Developer
- Beckman Coulter
- Intended use
- Risk Stratification
- Cancer scope
- Prostate cancer
- Specimen
- Serum
- Molecular modality
- Protein
- Current version
- Current Prostate Health Index (phi) configuration (2026-09)
- Evidence context
- 0 structured studies · 0 indexed performance results · 2 sources
Why can reported performance numbers differ? MDI keeps each result attached to its study, population, stage or stratum, test version and source rather than treating performance as a fixed property of the test.